Apply to trial NCT07428499

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 3Drug trial

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

Study ADX-324-302 is an extension study for participants who complete the Phase 3 ADX-324-301 trial. The extension study will provide information about the safety and efficacy of additional dosing of ADX-324 in participants with Type I and Type II hereditary angioedema (HAE). The study will also include pharmacodynamic (PD), pharmacokinetic (PK), and health-related quality of life (HRQoL) measurements.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening